MBX Biosciences, Inc. (MBX) is a publicly traded company in the Unknown sector. Across all available filings, 20 corporate insiders have executed 54 transactions totaling $148.5M, demonstrating a bullish sentiment with $148.5M in net insider flow. The most recent transaction on Jan 20, 2026 involved a transaction of 32,000 shares valued at $0.
No significant insider buying has been recorded for MBX in the recent period.
No significant insider selling has been recorded for MBX in the recent period.
Based on recent SEC filings, insider sentiment for MBX is bullish with an Insider Alignment Score of 100/100 and a net flow of $148.5M. Insiders are accumulating shares, which historically signals confidence in the company's future performance.
Insider trading at MBX Biosciences, Inc. (MBX) refers to stock transactions made by corporate insiders—executives, directors, and beneficial owners holding more than 10% of the company's shares. These individuals have access to material non-public information and are required by law to report their trades to the SEC within two business days. Currently, 20 insiders are actively trading MBX stock, having executed 54 transactions in the past 90 days. The most active insider is X, L.p. Fhmls (Executive), who has made 3 transactions totaling $22.0M.
Get notified when executives and directors at MBX file new Form 4 transactions
Date | Insider | Title | Type | Shares | Price | Value | Flags |
|---|---|---|---|---|---|---|---|
| Jan 20, 2026 | Stelzer Laurie | Executive | Award | 32,000 | $N/A | $0 | |
| Oct 24, 2025 | Kent Hawryluk P. | Executive | Option Exercise | 182,859 | $3.25 | $594.3K | Large |
| Oct 20, 2025 | Kent Hawryluk P. | Executive | Purchase | 20,000 | $13.64 | $272.8K | |
| Oct 17, 2025 | L. Hoerter Steven | Executive | Purchase | 20,000 | $13.25 | $265.0K | |
| Sep 26, 2025 | L.p. Fhmls X, | Executive | Purchase | 666,666 | $18.00 | $12.0M | Large |
| Sep 16, 2024 | Innovation Master Investors (cayman) II L.p. Wellington Biomedical | Executive | Conversion | 403,787 | $N/A | $0 | |
| Sep 16, 2024 | Innovation Master Investors (cayman) II L.p. Wellington Biomedical | Executive | Conversion | 1,386,335 | $N/A | $0 | |
| Sep 16, 2024 | L. Gordon Carl | Executive | Conversion | 403,787 | $N/A | $0 | |
| Sep 16, 2024 | L. Gordon Carl | Executive | Conversion | 2,658,428 | $N/A | $0 | |
| Sep 16, 2024 | L. Gordon Carl | Executive | Purchase | 250,000 | $16.00 | $4.0M | Large |
| Sep 16, 2024 | L. Gordon Carl | Executive | Purchase | 500,000 | $16.00 | $8.0M | Large |
| Sep 16, 2024 | Aynechi Tiba | Executive | Conversion | 1,386,335 | $N/A | $0 | |
| Sep 16, 2024 | Aynechi Tiba | Executive | Purchase | 750,000 | $16.00 | $12.0M | Large |
| Sep 16, 2024 | Kent Hawryluk P. | Executive | Conversion | 115,914 | $N/A | $0 | |
| Sep 16, 2024 | Kent Hawryluk P. | Executive | Conversion | 283,846 | $N/A | $0 |
| TYPE | COUNT | VALUE | % |
|---|---|---|---|
Purchase(P) | 20 | $148.5M | 99.6% |
Exercise(M) | 1 | $594.3K | 0.4% |
Award(A) | 1 | $0 | 0.0% |
Conversion(C) | 32 | $0 | 0.0% |
Insiders at MBX Biosciences, Inc. are accumulating shares at an accelerated pace. With 20 insiders making 54 transactions totaling $148.5M in purchases versus $0 in sales, the net buying activity of $148.5M signals strong executive confidence. X, L.p. Fhmls (Executive) leads the buying activity with $22.0M in transactions across all time.